<DOC>
	<DOC>NCT02835118</DOC>
	<brief_summary>This study aims to assess the safety, tolerability, and pharmacokinetics (PK) of oral doses of surotomycin (CB-183,315) administered for 14 consecutive days in healthy males and females.</brief_summary>
	<brief_title>A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<criteria>Has no evidence of prior chronic gastrointestinal inflammatory disease such as inflammatory bowel disease Electrocardiogram (ECG) shows no clinically significant abnormalities Is in good health Pregnant or lactating females Has prior exposure to surotomycin Has received an investigational drug or participated in any experimental procedure within1 month prior to study entry and at least 6 half lives from last intake of study drug Participants 18 to 49 years of age that has taken any regular, prescribed, or overthecounter medication Has any significant concurrent therapies Has a positive drug screen Has a positive human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C screen Has donated blood or blood products in the 60 days preceding screening Is an active intravenous drug user or abuses alcohol Has had a malignancy within the last 5 years Has inadequate protection against pregnancy during the conduct of the study and until 1 month after last dose of study drug Has received any antibiotics within 30 days prior to first dose of study drug Has known hypersensitivity to daptomycin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>